Thomas Martin, MD, on the Benefits of Cilta-Cel in R/R Multiple Myeloma
Thomas Martin, MD, spoke about which patient population with relapsed/refractory multiple myeloma would benefit most from treatment with ciltacabtagene autoleucel.
Thomas Martin, MD, associate director of the myeloma program at the University of California San Francisco, spoke with CancerNetwork®about the approval of ciltacabtagene autoleucel (Carvykti; cilta-cel) and which patients he thought might benefit most from this therapy.1 This approval comes based on the results of the phase 1b/2 CARTITUDE-1 trial (NCT03548207) in which patients with heavily pretreated myeloma were given cilta-cel and saw durable responses. Martin says that those who are in good physical health are most likely to endure treatment with the CAR T-cell therapy.2
Transcript:
We try to look at what the difference is between eligibility for an autologous transplant, eligibility for a CAR T-cell therapy, or [eligibility] for any off-the-shelf product? For most people who are older than age 70, or older than age 75 years, we have a difficult time [conducting] an autologous transplant because it’s a tough treatment.
CAR T-cells can be [manufactured for] patients that are 8 years old and patients that are in their mid 80s if that patient is fit. I [ask patients] ‘if you walk [the distance of] 2 telephone poles, do you need oxygen? If you don’t, do you get chest pain?’ If you don’t, you’re eligible for CAR T-cell therapy. We can make it so that a larger population than [those] who are eligible for an autologous transplant can get this CAR T-cell therapy. Anybody who is fit, age independent, [who can] walk into the doctor’s office, jump in the chair, jump up on doctors table, etc, is likely fit enough to go through CAR T-cell therapy. It’s going to be a broad patient population. That’s why the need is so high [for this treatment].
References
- U.S. FDA Approves CARVYKTI (ciltacabtagene autoleucel), Janssen's first cell therapy, a BCMA-directed CAR-T immunotherapy for the treatment of patients with relapsed or refractory multiple myeloma. News release. Janssen. February 28, 2022. Accessed February 28, 2022. https://prn.to/3vskiZu
- Martin T, Usmani S, Berdeja J, et al. Updated Results from CARTITUDE-1: Phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma. Blood. 2021;138(suppl 1):549. doi:10.1182/blood-2021-146060
FDA Approves Cilta-Cel for Relapsed/Refractory Myeloma After 1 Therapy
April 6th 2024The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of treatment, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.
